Elite Pharmaceuticals Inc (ELTP)

Healthcare | Drug Manufacturers Specialty Generic
Income Statement (Quarterly) 2025-06-30 2024-12-31 2024-09-30 2024-06-30
Revenue 40,211,097 14,364,248 18,880,345 18,803,063
Cost of Revenue 12,985,127 8,244,907 10,682,917 10,328,285
Gross Profit 27,225,970 6,119,341 8,197,428 8,474,778
Operating Expenses
R&D Expenses 0 0 0 0
SG&A Expenses 3,456,413 2,724,616 2,326,073 2,021,483
Operating Expenses 5,526,263 5,021,531 4,712,485 4,185,010
Operating Income 21,699,707 1,097,810 3,484,943 3,864,056
Interest Expense 158,926 77,607 255,136 250,781
Income Before Tax -564,214 -10,652,765 -9,519,026 847,752
Income Tax Expense 5,320,501 239,175 1,517,203 231,979
Net Income -5,884,715 -10,891,940 -11,036,229 615,773
Per Share
EPS -0.01 -0.01 -0.01 0.00
EPS Diluted 0.00 0.00 0.00 0.00
Income Statement (Annual) 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Revenue 84,043,929 56,625,128 34,155,114,000 32,262,117 25,380,749
Cost of Revenue 43,957,274 30,268,025 17,561,093,000 17,466,763 13,513,611
Gross Profit 40,086,655 26,357,103 16,594,021,000 14,795,354 11,867,138
Operating Expenses
R&D Expenses 0 0 0 0 0
SG&A Expenses 9,229,495 7,305,035 5,122,272,000 4,478,356 3,336,226
Operating Expenses 20,486,187 15,568,334 12,918,019,000 9,724,644 9,762,615
Operating Income 19,600,468 10,788,769 2,025,111,000 5,070,710 2,104,523
Interest Expense 772,367 588,622 1,112,707 191,816 259,598
Income Before Tax -52,140 463,092 3,985,874,000 6,304,429 4,144,514
Income Tax Expense 4,262,519 -19,645,539 -424,028,000 -1,736,437 -943,907
Net Income -4,314,659 20,108,631 4,409,902,000 8,898,245 5,088,421
Per Share
EPS 0.00 0.02 4.35 0.01 0.01
EPS Diluted 0.00 0.00 0.00 0.00 0.00
Balance Sheet (Quarterly) 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Assets
Cash and Cash Equivalents 11,315,385 7,106,262 7,832,247 8,535,357
Short Term Investments 0 0 0 0
Net Receivables 29,207,028 19,453,301 3,094,549 3,057,913
Inventory 16,240,376 12,930,464 9,550,716 6,741,170
Total Current Assets 57,739,147 40,014,189 21,510,297 18,861,389
Property Plant Equipment 14,099,023 14,610,152 10,439,220 6,984,876
Goodwill and Intangibles 5,637,802 6,341,228 6,341,228 6,634,035
Total Assets 96,387,477 83,653,536 40,896,018 35,148,898
Liabilities
Account Payables 2,957,584 2,714,306 2,446,810 1,430,985
Short Term Debt 5,082,068 5,020,378 325,768 556,781
Total Current Liabilities 11,840,435 13,049,764 7,833,637 6,694,241
Long Term Debt 5,832,820 6,717,390 3,561,520 2,224,787
Total Liabilities 42,872,448 26,070,718 11,935,758 9,926,871
Shareholders Equity
Retained Earnings -120,703,926 -116,389,267 -136,497,898 -140,059,744
Total Shareholders Equity 53,515,029 57,582,818 28,960,260 25,222,027
Balance Sheet (Annual) 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Assets
Cash and Cash Equivalents 11,315,385 7,106,262 7,832,247 8,535,357 3,192,768
Short Term Investments 0 0 0 0 0
Net Receivables 29,207,028 19,453,301 3,094,549 3,057,913 3,496,376
Inventory 16,240,376 12,930,464 9,550,716 6,741,170 5,012,902
Total Current Assets 57,739,147 40,014,189 21,510,297 18,861,389 12,194,667
Property Plant Equipment 14,099,023 14,610,152 10,439,220 6,984,876 6,864,039
Goodwill and Intangibles 5,637,802 6,341,228 6,341,228 6,634,035 6,634,035
Total Assets 96,387,477 83,653,536 40,896,018 35,148,898 26,189,492
Liabilities
Account Payables 2,957,584 2,714,306 2,446,810 1,430,985 929,690
Short Term Debt 5,082,068 5,020,378 325,768 556,781 598,908
Total Current Liabilities 11,840,435 13,049,764 7,833,637 6,694,241 5,812,531
Long Term Debt 5,832,820 6,717,390 3,561,520 2,224,787 1,779,600
Total Liabilities 42,872,448 26,070,718 11,935,758 9,926,871 10,037,563
Shareholders Equity
Retained Earnings -120,703,926 -116,389,267 -136,497,898 -140,059,744 -148,957,989
Total Shareholders Equity 53,515,029 57,582,818 28,960,260 25,222,027 16,151,929
Cash Flow Statement (Quarterly) 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Operating Activities
Net Income -4,314,659 20,108,631 3,561,846 8,898,245
Depreciation & Amortization 2,122,343 1,471,584 1,344,683 1,434,709
Stock Based Compensation 227,565 8,513,927 579,325 781,475
Change in Working Capital -15,166,285 -11,880,605 -2,025,634 -1,010,037
Operating Cash Flow 7,455,639 -3,281,558 3,338,704 6,508,314
Investing Activities
Capital Expenditure -2,525,082 -809,653 -5,736,618 -498,566
Investments -1,625,082 -809,653 -5,736,618 -498,566
Investing Cash Flow -2,399,832 -809,653 -5,736,618 -498,566
Financing Activities
Debt Repayment -845,045 3,339,181 -12,736,786 -667,133
Common Stock Issued/Repurchased 19,305 159,921,000 39,325,000 14,353,000
Dividends Paid 0 0 0 0
Financing Cash Flow -825,740 3,385,624 1,702,199 -667,133
Summary
Free Cash Flow 4,930,557 -4,091,211 -2,397,914 6,009,748
Net Change in Cash 4,230,067 -705,587 -695,715 5,342,615
Cash Flow Statement (Annual) 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Operating Activities
Net Income -4,314,659 20,108,631 3,561,846 8,898,245 5,088,421
Depreciation & Amortization 2,122,343 1,471,584 1,344,683 1,434,709 1,524,591
Stock Based Compensation 227,565 8,513,927 579,325 781,475 935,624
Change in Working Capital -15,166,285 -11,880,605 -2,025,634 -1,010,037 -2,057,886
Operating Cash Flow 7,455,639 -3,281,558 3,338,704 6,508,314 3,193,861
Investing Activities
Capital Expenditure -2,525,082 -809,653 -5,736,618 -498,566 -329,981
Investments -1,625,082 -809,653 -5,736,618 -498,566 -329,981
Investing Cash Flow -2,399,832 -809,653 -5,736,618 -498,566 -262,781
Financing Activities
Debt Repayment -845,045 3,339,181 -12,736,786 -667,133 -1,925,532
Common Stock Issued/Repurchased 19,305 159,921,000 39,325,000 14,353,000 42,223
Dividends Paid 0 0 0 0 0
Financing Cash Flow -825,740 3,385,624 1,702,199 -667,133 -869,829
Summary
Free Cash Flow 4,930,557 -4,091,211 -2,397,914 6,009,748 2,863,880
Net Change in Cash 4,230,067 -705,587 -695,715 5,342,615 2,061,251